A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer
NCT00147485
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
37
Enrollment
INDUSTRY
Sponsor class
Stopped
See Detailed Description
Conditions
Neoplasms
Lymphoma, Non-Hodgkin
Interventions
DRUG:
AG-024322
Sponsor
Pfizer